Actively Recruiting
Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE
Led by Sichuan Provincial People's Hospital · Updated on 2026-05-12
5138
Participants Needed
1
Research Sites
136 weeks
Total Duration
On this page
Sponsors
S
Sichuan Provincial People's Hospital
Lead Sponsor
F
Fudan University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this clinical trial is to evaluate the efficacy and safety of platelet aggregation function - guided precision anti - platelet therapy in patients with acute cerebral infarction. The main question it aims to answer is: among the cerebral infarction patients with possible clopidogrel resistance detected by platelet aggregation function tests, what is the efficacy and safety of using ticagrelor to replace the clopidogrel treatment regimen.
CONDITIONS
Official Title
Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with acute non-disabling ischemic stroke (NIHSS score 5 or less) or transient ischemic attack with moderate to high stroke risk (ABCD2 score 4 or higher)
- Time from symptom onset to treatment 48 hours or less
- Platelet aggregation function test (MARADP) 35% or higher after antiplatelet therapy
- Provided written informed consent by patient or legal representative
You will not qualify if you...
- Imaging indicating hemorrhagic stroke, hemorrhagic transformation, or other cerebral disorders like vascular malformations, tumors, or abscesses
- Stroke or TIA caused by angioplasty or vascular surgery
- ECG or physical signs suggesting atrial fibrillation
- Need for anticoagulant therapy due to suspected cardiogenic embolism
- Received or planned thrombolysis, mechanical thrombectomy, or revascularization surgery within 90 days
- Use of antiplatelet agents other than aspirin or clopidogrel within 7 days
- Recent history of gastrointestinal bleeding, intracranial hemorrhage, massive bleeding, or blood transfusion
- Contraindications or intolerance to clopidogrel, ticagrelor, or aspirin including allergy, severe liver or kidney problems, severe heart failure, coagulation disorders, blood cell disorders, or drug-induced blood or liver diseases
- Low white blood cell or platelet counts
- Use of heparin or oral anticoagulants within 10 days prior to enrollment
- Severe cardiac, lung, liver, or kidney disease or other serious illnesses
- Women of childbearing age refusing contraception, pregnant or breastfeeding
- Poor compliance or inability to cooperate with study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China, 610072
Actively Recruiting
Research Team
J
Jie Yang Deputy Director of the Department of Neurology
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here